title: Hormone therapy: an overview.
abstract: Hormonal treatment of prostate cancer has advanced little in the past 20 years. Total androgen ablation may offer a 20% survival advantage when compared with monotherapy, as might the use of stilboestrol if its cardiovascular side-effects could be abolished with aspirin or some other agent. Neither approach, however, is likely to lead to a cure. Currently available cytotoxic chemotherapy appears to offer little survival advantage. There is an urgent need for the development of other treatments.
authors.affiliation: Department of Urology, St James's Hospital, Leeds.
authors.forename: P H
authors.initials: PH
authors.lastname: Smith
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D002319:Cardiovascular System / Q000187:drug effects; D004054:Diethylstilbestrol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D000726:Androgen Antagonists; D004054:Diethylstilbestrol